Triple9 Friday, 09/29/17 04:42:54 PM Re: None Post # of 4859 Why $GWPH was down today: GW Pharma slips 15% premarket on Zogenix's successful late-stage study of ZX008 in Dravet Sep. 29, 2017 7:48 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor GW Pharmaceuticals (NASDAQ:GWPH) is down 15% premarket, albeit on only 779 shares, in apparent response to Zogenix's announcement of positive Phase 3 results for Dravet syndrome candidate ZX008. GW's late-stage candidate for Dravet is Epidiolex (cannabidiol). Previously: Zogenix's lead candidate ZX008 successful in late-stage Dravet study (Sept. 29) Previously: GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome (April 21, 2015) https://seekingalpha.com/news/3298365-gw-pharma-slips-15-percent-premarket-zogenixs-successful-late-stage-study-zx008-dravet I dislike linking Seeking Alpha articles but this one seems to be dead on. Know What You Own. My posts should not be construed as investment advice.